Ghofrani, Hossein-Ardeschir <br/><br/>
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.  [electronic resource] 

 -  The Lancet. Respiratory medicine  10 2017 
 - 785-794 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Retracted Publication 
<br/><br/><label>ISSN: </label>2213-2619 
<br/><br/><label>Standard No.: </label>10.1016/S2213-2600(17)30305-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Chronic Disease<br/>Double-Blind Method<br/>Endothelin Receptor Antagonists--administration & dosage<br/>Female<br/>Humans<br/>Hypertension, Pulmonary--drug therapy<br/>Male<br/>Middle Aged<br/>Natriuretic Peptide, Brain--drug effects<br/>Peptide Fragments--drug effects<br/>Pulmonary Embolism--drug therapy<br/>Pyrimidines--administration & dosage<br/>Sulfonamides--administration & dosage<br/>Treatment Outcome<br/>Vascular Resistance--drug effects